NO20050827L - Anvendelse av interferon-B ved behandling av nyresvikt - Google Patents

Anvendelse av interferon-B ved behandling av nyresvikt

Info

Publication number
NO20050827L
NO20050827L NO20050827A NO20050827A NO20050827L NO 20050827 L NO20050827 L NO 20050827L NO 20050827 A NO20050827 A NO 20050827A NO 20050827 A NO20050827 A NO 20050827A NO 20050827 L NO20050827 L NO 20050827L
Authority
NO
Norway
Prior art keywords
treatment
renal failure
interferon
drugs
ifn
Prior art date
Application number
NO20050827A
Other languages
English (en)
Norwegian (no)
Inventor
Roy R Lobb
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of NO20050827L publication Critical patent/NO20050827L/no

Links

Classifications

    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L47/00—Traffic control in data switching networks
    • H04L47/50—Queue scheduling
    • H04L47/62—Queue scheduling characterised by scheduling criteria
    • H04L47/6285—Provisions for avoiding starvation of low priority queues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L47/00—Traffic control in data switching networks
    • H04L47/10—Flow control; Congestion control
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L47/00—Traffic control in data switching networks
    • H04L47/10—Flow control; Congestion control
    • H04L47/215—Flow control; Congestion control using token-bucket
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W28/00—Network traffic management; Network resource management
    • H04W28/02—Traffic management, e.g. flow control or congestion control
    • H04W28/0252—Traffic management, e.g. flow control or congestion control per individual bearer or channel
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W28/00—Network traffic management; Network resource management
    • H04W28/02—Traffic management, e.g. flow control or congestion control
    • H04W28/0278—Traffic management, e.g. flow control or congestion control using buffer status reports
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W72/00—Local resource management
    • H04W72/20—Control channels or signalling for resource management
    • H04W72/23—Control channels or signalling for resource management in the downlink direction of a wireless link, i.e. towards a terminal
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W8/00—Network data management
    • H04W8/02—Processing of mobility data, e.g. registration information at HLR [Home Location Register] or VLR [Visitor Location Register]; Transfer of mobility data, e.g. between HLR, VLR or external networks
    • H04W8/04—Registration at HLR or HSS [Home Subscriber Server]
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W72/00—Local resource management
    • H04W72/12—Wireless traffic scheduling

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Databases & Information Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Mobile Radio Communication Systems (AREA)
NO20050827A 2002-07-17 2005-02-16 Anvendelse av interferon-B ved behandling av nyresvikt NO20050827L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39639302P 2002-07-17 2002-07-17
PCT/US2003/022440 WO2004006756A2 (en) 2002-07-17 2003-07-17 THERAPIES FOR RENAL FAILURE USING INTERFERON-β

Publications (1)

Publication Number Publication Date
NO20050827L true NO20050827L (no) 2005-04-15

Family

ID=30116023

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050827A NO20050827L (no) 2002-07-17 2005-02-16 Anvendelse av interferon-B ved behandling av nyresvikt

Country Status (20)

Country Link
US (1) US20070025965A1 (xx)
EP (1) EP1553971A4 (xx)
JP (2) JP4883665B2 (xx)
KR (2) KR20110053390A (xx)
CN (2) CN101664545A (xx)
AU (1) AU2003256603C1 (xx)
BR (1) BR0312947A (xx)
CA (1) CA2492649A1 (xx)
EA (1) EA009938B1 (xx)
GE (1) GEP20084499B (xx)
IL (2) IL166256A (xx)
IS (1) IS7650A (xx)
MX (1) MXPA05000658A (xx)
NO (1) NO20050827L (xx)
NZ (1) NZ538217A (xx)
PL (1) PL374914A1 (xx)
RS (1) RS20050035A (xx)
UA (1) UA88440C2 (xx)
WO (1) WO2004006756A2 (xx)
ZA (1) ZA200500342B (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519840A (ja) 2004-11-10 2008-06-12 ジェンザイム・コーポレイション 糖尿病の処置方法
BRPI0520498B8 (pt) 2005-08-26 2021-05-25 Ares Trading Sa processo para fabricação de interferon beta humano recombinante glicosilado, e uso de um meio de cultura isento de soro
US8604175B2 (en) 2005-12-09 2013-12-10 Ares Trading S.A. Method for purifying FSH or a FSH mutant
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US7553941B2 (en) * 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
ES2546181T3 (es) 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
KR101532369B1 (ko) * 2006-12-11 2015-06-29 삼성전자주식회사 휴대용 단말기의 원격제어 장치 및 방법
EP2167485B1 (en) 2007-05-31 2015-09-30 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
MX2010003603A (es) 2007-10-05 2010-06-02 Genzyme Corp Metodo para el tratamiento de enfermedades de riñon poliquisticas con derivados de ceramida.
US20100249381A1 (en) * 2007-10-22 2010-09-30 David Delvaille Method for Purifying FC-Fusion Proteins
EP3595264B1 (en) * 2007-10-27 2021-04-07 BlackBerry Limited Content disposition system and method for processing message content in a distributed environment
SI2234645T1 (sl) * 2007-12-20 2012-07-31 Merck Serono Sa Formulacije peg interferon beta
CA2731685A1 (en) * 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
MX2011003517A (es) 2008-10-03 2011-05-25 Genzyme Corp Inhibidores de la glucosilceramida sintasa tipo 2-acilaminopropanol.
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
CN103228290A (zh) * 2011-02-18 2013-07-31 (株)斯坦帝尔 包含沉默信息调节因子1表达诱导物质的败血症或者败血性休克的预防或者治疗用组合物
EP2838552A4 (en) 2012-04-19 2016-05-18 Opko Biolog Ltd OXYNTOMODULIN VARIANTS WITH EXTENDED ACTION AND PROCESSES FOR PRODUCING SAME
WO2014080401A2 (en) 2012-11-20 2014-05-30 Prolor Biotech Inc Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
CN113289009A (zh) 2015-06-19 2021-08-24 Opko生物科学有限公司 长效凝固因子及其产生方法
FI126979B (en) 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyophilized pharmaceutical formulation and use thereof
CN118085104A (zh) 2016-07-11 2024-05-28 Opko生物科学有限公司 长效凝血因子及其制备方法
RU2728696C2 (ru) * 2018-12-28 2020-07-30 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Моноклональное антитело к интерферону бета-1а человека

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2210622A1 (en) * 1995-11-17 1997-05-29 Toray Industries, Inc. An agent protecting endothelial cells
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
ATE327254T1 (de) * 1998-10-16 2006-06-15 Biogen Idec Inc Interferon-beta fusionsproteine und deren verwendungen
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US6894033B2 (en) * 2001-06-11 2005-05-17 Transition Therapeutics Inc. Combination therapies using vitamin B12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases

Also Published As

Publication number Publication date
IL200892A (en) 2014-11-30
IL200892A0 (en) 2010-05-17
EA200500218A1 (ru) 2006-08-25
EP1553971A4 (en) 2006-07-05
GEP20084499B (en) 2008-10-10
NZ538217A (en) 2007-04-27
WO2004006756A2 (en) 2004-01-22
WO2004006756A3 (en) 2004-08-19
EA009938B1 (ru) 2008-04-28
JP4883665B2 (ja) 2012-02-22
CA2492649A1 (en) 2004-01-22
EP1553971A2 (en) 2005-07-20
AU2003256603A1 (en) 2004-02-02
US20070025965A1 (en) 2007-02-01
BR0312947A (pt) 2007-07-10
CN101664545A (zh) 2010-03-10
IL166256A (en) 2010-11-30
JP2011144204A (ja) 2011-07-28
KR20110053390A (ko) 2011-05-20
CN1681527A (zh) 2005-10-12
UA88440C2 (ru) 2009-10-26
AU2003256603C1 (en) 2010-07-15
IS7650A (is) 2005-01-14
AU2003256603B2 (en) 2009-07-30
IL166256A0 (en) 2006-01-15
RS20050035A (xx) 2007-06-04
KR20050021502A (ko) 2005-03-07
PL374914A1 (en) 2005-11-14
JP2005537269A (ja) 2005-12-08
ZA200500342B (en) 2006-07-26
MXPA05000658A (es) 2005-08-19

Similar Documents

Publication Publication Date Title
NO20050827L (no) Anvendelse av interferon-B ved behandling av nyresvikt
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
FR16C0028I2 (fr) Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
NO20050427L (no) Carvedilolfosfatsalter og/eller solvater derav, tilsvarende preparater og/eller behandlingsfremgangsmater
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
ATE472551T1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
PL371736A1 (en) Method for administering glp-1 molecules
NO20055516L (no) Kannabinoidreceptorligander og anvendelser derav
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
BRPI0912411B8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune
NO20053126D0 (no) Kontrollsystem for medisinsk behandling.
BRPI0512500A (pt) tratamento ou condições envolvendo desmielinação
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
NO20064584L (no) Tetrahydropyridoindolderivater
BRPI0416268A (pt) composições de delta-9-thc e métodos para o tratamento de sintomas associados à esclerose múltipla
BRPI0612840A8 (pt) Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
IS7746A (is) Meðferðir á þrálátum bólgutengdum afmýlunarfjöltaugakvilla með því að nota beta interferon
NO20076405L (no) Anvendelse av 24-nor-UDCA
NO20060420L (no) 2-aminobenzoylderivater
NO20073901L (no) Anvendelse av ostrogen reseptor-B selektive agonister for bestralnings- eller kjemoterapi indusert mucosistis og bestralningscystis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application